Roche trumpets data for Soliris rival in NMOSD after US, EU filings

Roche trumpets data for Soliris rival in NMOSD after US, EU filings

Source: 
Pharmaforum
snippet: 

Roche has continued to build the case for satralizumab, its experimental therapy for rare disease neuromyelitis optica spectrum disorder (NMOSD), which is heading for approval decision in the US and Europe next year.